| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sézary syndrome (SS) is a rare lymphoproliferative neoplasm, almost
incurable outside the setting of allogeneic transplantable patients.
The prognosis for relapsed/refractory patients remains poor, as the
available drugs confer short-lasting remission. In this setting, the
anti-chemokine receptor type 4 (CCR4) monoclonal antibody mogamulizumab
demonstrated efficacy in an international, open-label, randomized
controlled phase 3 trial (MAVORIC) versus vorinostat.
|Figure 1. Patient before starting treatment (A, back; B, legs).|
|Figure 2. Patient after achieving a complete response (A, back; B, legs).|